Although these 4 trials established the clinical benefit of dual therapy with a DOAC and P2Y12 inhibitor as compared with a warfarin‐based triple therapy in AF patients with CAD, the endpoints in the trials were only evaluated during a limited duration of 1 year after PCI. Here, P2RY12 is linked to coronary artery disorder.